|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glioma stem cells (GSCs) significantly contribute to GBM progression and post-treatment tumor relapse, therefore serving as a key therapeutic target; however, GSCs are resistant to conventional radiation therapy.
|
26354413 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hESC methylator-negative phenotype has demonstrated poor survival and upregulation of glioma stem cell (GSC) markers, and is enriched in one of the previously defined transcriptomic phenotypes-the mesenchymal phenotype.
|
24601786 |
2014 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies showed Demethoxycurcumin (DMC) has stronger anti-glioma and anti-GSCs effects both in vitro and in vivo.
|
29575236 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Live-cell imaging, in vitro PDT, and in vivo studies were performed to elucidate the effect lapatinib had on PDT for a variety of glioma cell lines and as well as GSC-30 neurospheres in vivo.
|
31847378 |
2019 |
|
Conductive hearing loss
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Micrognathism
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Microstomia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Feeding difficulties
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Byzanthine arch palate
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Congenital dislocation of radial head
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Preauricular dimple
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Flexion contracture
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Short stature
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Downward slant of palpebral fissure
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Sunken eyes
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Orbital separation diminished
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study discovers a previously unrecognized role of AEG-1 in GSC biology and supports the significance of this gene as a potential therapeutic target for glioblastoma multiforme.
|
27903708 |
2017 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, basic GBM and GSC genetics and proteomics studies combined with strategies to discover GSC-targeting agents could lead to novel treatments that significantly improve patient survival and quality of life.
|
24657832 |
2014 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of studies suggest that a fraction of tumor cells with stem cell features (Glioma Stem-like Cells, GSC) might be responsible for GBM recurrence and aggressiveness.
|
23284888 |
2012 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glioma stem cells (GSCs) significantly contribute to GBM progression and post-treatment tumor relapse, therefore serving as a key therapeutic target; however, GSCs are resistant to conventional radiation therapy.
|
26354413 |
2015 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy.
|
28419967 |
2017 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
A t<i>G</i>LI1 activation signature (tGAS) correlated with glioma grade, tumor angiogenesis, and poor overall survival, and GBMs with high tGAS were enriched with mesenchymal GBM/GSC gene signatures.
|
29463580 |
2018 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to find new GB/GSC marker candidates that would be cell surface proteins (CSP), we have performed meta-analysis of genome-scale mRNA expression data from three data repositories (GEO, ArrayExpress and GLIOMASdb).
|
29734672 |
2018 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings indicate that EGFR inhibition in GBM induces MET activation in GSCs, which is a functional requisite for GSCs activity and thus represents a promising therapeutic target.
|
24115218 |
2014 |
|
Glioblastoma Multiforme
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that Wnt/β-catenin signaling is a key downstream effector of MET signaling and contributes to the maintenance of GSC and GBM malignancy.
|
23258844 |
2013 |